SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

SANES

10.692

+1.95%↑

BBVA

19.865

+2.56%↑

BNP

92.21

+2.54%↑

CABK

11.67

+1.97%↑

INGA

27.035

+2.21%↑

Home・Listă Acțiuni・Bayer AG

Bayer AG

Deschisă

SectorFinanțe

38.61 0.44

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

38.39

Maxim

38.78

Indicatori cheie
By Trading Economics
Venit	6.5B 2.8B
Vânzări	2B 13B
EPS	2.812
Randament dividend	0.29
Marjă de profit	20.612
Angajați	87,757
EBITDA	2.3B 4.4B

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+25.11% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.29% 4.64%
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	737M 37B
Deschiderea anterioară	38.17
Închiderea anterioară	38.61

Sentimentul știrilor

By Acuity

34%

66%

91 / 438 Clasament în Finance

Bayer AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2026, 11:24 UTC

Câștiguri

Principalele dinamici ale pieței

Bayer Shares Climb After Earnings Beat Expectations

12 mai 2026, 06:10 UTC

Câștiguri

Bayer Net Profit Surges Driven by Growth in Agricultural Division

6 mai 2026, 10:51 UTC

Achiziții, Fuziuni, Preluări

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion -- Update

6 mai 2026, 07:01 UTC

Achiziții, Fuziuni, Preluări

Bayer to Buy Eye-Drug Developer Perfuse Therapeutics for Up to $2.45 Billion

12 mai 2026, 12:05 UTC

Acțiuni populare

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 mai 2026, 10:51 UTC

Acțiuni populare

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 mai 2026, 09:08 UTC

Acțiuni populare

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

12 mai 2026, 05:38 UTC

Câștiguri

Bayer Backs 2026 Outlook Adjusted for Currency

12 mai 2026, 05:36 UTC

Câștiguri

Bayer 1Q Consumer Health Sales Grew 5.3%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:36 UTC

Câștiguri

Bayer 1Q Pharma Sales Fell 0.5%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:36 UTC

Câștiguri

Bayer 1Q Crop Science Sales Grew 6.8%, Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:35 UTC

Câștiguri

Bayer 1Q Adj EPS EUR2.71

12 mai 2026, 05:34 UTC

Câștiguri

Analysts Saw Bayer 1Q Net Profit From Continuing Operations at EUR1.60B

12 mai 2026, 05:34 UTC

Câștiguri

Analysts Saw Bayer 1Q Ebitda Before Special Items at EUR3.93B

12 mai 2026, 05:34 UTC

Câștiguri

Analysts Saw Bayer 1Q Sales at EUR13.42B

12 mai 2026, 05:34 UTC

Câștiguri

Bayer 1Q Sales Grew 4.1% When Adjusted for Currency, Portfolio Changes

12 mai 2026, 05:33 UTC

Câștiguri

Bayer 1Q EBIT EUR3.53B

12 mai 2026, 05:32 UTC

Câștiguri

Bayer 1Q Ebitda Before Special Items EUR4.45B

12 mai 2026, 05:32 UTC

Câștiguri

Bayer 1Q Net Pft EUR2.76B

12 mai 2026, 05:31 UTC

Câștiguri

Bayer 1Q Sales EUR13.405B

12 mai 2026, 05:31 UTC

Câștiguri

Bayer Backs 2026 View

6 mai 2026, 06:34 UTC

Achiziții, Fuziuni, Preluări

Bayer: Perfuse's Lead Program Is Treatment for Glaucoma and Diabetic Retinopathy

6 mai 2026, 06:33 UTC

Achiziții, Fuziuni, Preluări

Bayer: Acquisition Aims to Complement Ophthalmology Pipeline

6 mai 2026, 06:33 UTC

Achiziții, Fuziuni, Preluări

Bayer: Additional Payments Subject to Development, Regulatory, and Commercial Milestones

6 mai 2026, 06:32 UTC

Achiziții, Fuziuni, Preluări

Bayer to Pay $300M Upfront

6 mai 2026, 06:32 UTC

Achiziții, Fuziuni, Preluări

Bayer to Buy Perfuse Therapeutics for Up to $2.45B

6 mai 2026, 06:31 UTC

Achiziții, Fuziuni, Preluări

Bayer to Buy Perfuse Therapeutics

6 mai 2026, 06:30 UTC

Achiziții, Fuziuni, Preluări

Bayer To Acquire Perfuse Therapeutics To Complement Ophthalmology Pipeline >BAYN.XE

8 apr. 2026, 14:41 UTC

Câștiguri

Buy Johnson & Johnson Stock Ahead of Earnings, Analyst Says. The Gains Can Continue. -- Barrons.com

1 apr. 2026, 14:24 UTC

Market Talk

Bayer Pharma Head Touts Healthiest Pipeline in Company's History -- Market Talk

Comparație

Modificare preț

Bayer AG Așteptări

Obiectiv de preț

By TipRanks

25.11% sus

Prognoză pe 12 luni

Medie 48.18 EUR 25.11%

Maxim 56 EUR

Minim 25 EUR

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBayer AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

12 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 12 analiști care au acordat evaluări ale acțiunilor Bayer AG - Dist în ultimele 3 luni.

Sentiment

By Acuity

91 / 438 Clasament în Finanțe

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.